GoodRx Holdings, Inc. (NASDAQ:GDRX) is among the 12 Best American Penny Stocks to Buy Right Now. Goldman Sachs raised its price target from $3.75 to $4 on November 6 while maintaining a Neutral rating after the company’s third-quarter results. The company is expanding accessibility programs and exploring the TrumpRx initiative.

Goldman Sachs highlighted challenges in the industry, such as uncertainties about Affordable Care Act subsidies and Medicaid support. GoodRx Holdings, Inc. (NASDAQ:GDRX) saw strong performance in pharma manufacturer solutions in Q3 2025. The company’s new brand campaign aims to raise awareness of its consumer products, including subscription services for hair loss and weight loss treatments.

Despite potential regulatory changes and volatility risks, GoodRx Holdings, Inc. (NASDAQ:GDRX) remains focused on consumer affordability. The company’s digital healthcare platform connects various stakeholders in the medication industry to improve accessibility and affordability. Investors are advised to consider other AI stocks for greater upside potential and lower downside risk.

If you’re interested in investment opportunities, consider exploring AI stocks that offer significant potential benefits from Trump-era tariffs and the onshoring trend. For more insights on stocks under $20 and the best performing stocks in the last 3 months, visit Insider Monkey’s website. This article does not contain any promotional or marketing content.

Read more at Yahoo Finance: Goldman Sachs Raises GoodRx (GDRX) Price Target, Keeps Neutral Rating